Hypoglycemia in Prader-Willi Syndrome

NCT ID: NCT01897363

Last Updated: 2014-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will study whether infants with Prader-Willi Syndrome experience low blood sugars after short periods of fasting. This study will also evaluate metabolic markers in the blood to determine if infants with Prader-Willi Syndrome process energy differently than other children during fasting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will include outpatient admission to the clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast. A fast is when a person goes without food for a certain period of time. The participant will not be fasted longer than 6 hours.

The participant will arrive to the outpatient clinical research center at approximately 7am. A parent will be expected to stay with the participant at all times. The participant's finger will be poked for blood (requires approximately one drop of blood) soon after arrival to make sure his blood sugar is not already low. If the participant's blood sugar is low on arrival to the Clinical Research Center, additional blood will be drawn through his vein (a little more than half a teaspoon) and he will not have to complete the rest of the study. If his blood glucose is above 60 mg/dl, the participant will be given an opportunity to eat prior to starting the fast. A small tube will be placed in the participant's vein at the beginning of the fast to make additional blood draws easier. 1/10th a teaspoon of blood will be sent for cortisol testing when the IV is placed. Cortisol is a hormone that is important for control of blood sugar. In addition, the participant's finger will be pricked every hour for blood to monitor his blood sugar by bedside meter. Each finger prick will require approximately one to two drops of blood. A test to look at fat breakdown (ketones) will sometimes be checked using the same blood obtained when pricking the finger to check blood sugar. If a blood sugar of less than 70 mg/dl is found, blood sugars will be checked by finger prick every 30 minutes instead of every hour. If finger prick blood glucose is less than 65 mg/dl, blood will be collected and sent to the clinical research center lab to make sure that the true blood sugar reading is not lower than what is seen on the bedside meter (requires approximately 1/10 teaspoon of blood). If a blood sugar of less than 60 mg/dl is found, the fast will end and blood will be collected through the IV line (small tube placed through the vein). The participant will be monitored by a nurse during the fast. She will check his blood pressure, pulse and respiratory rate periodically to make sure he is comfortable. After final blood collection, the participant will be allowed to feed normally and his IV will be removed. During the entire study, we expect to collect at least ¾ of a teaspoon of blood from the participant. No more than 1.2 teaspoons of blood will be collected from the participant during this entire study.

If a blood sugar less than 60 mg/dl is found at any time, blood will be drawn from a vein in the participant's arm and the study will end. He will then be allowed to eat. If he has a low blood sugar and is unable to feed the way he normally does, sugar water/gel may be given by mouth or sugar water may be given by the tube placed in his vein. If the participant normally is fed by a tube placed in his stomach, sugar water may be given through this tube.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prader Willi Syndrome Hypoglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infants with Prader-Willi Syndrome

Infants between ages 2 to 12 months of age with Prader-Willi Syndrome.

Infants with Prader-Willi Syndrome

Intervention Type OTHER

Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Infants with Prader-Willi Syndrome

Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with Prader-Willi Syndrome
* Between ages 2-12 months of age
* Determined to be in nutritional phase 1a by clinical assessment

Exclusion Criteria

* Treatment with growth hormone
Minimum Eligible Age

2 Months

Maximum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Foundation for Prader-Willi Research

OTHER

Sponsor Role collaborator

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jennifer L Miller, MD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida

Gainesville, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

59-2013

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Preventing Hypoglycemia
NCT01923688 COMPLETED NA
Liver Glycogen and Hypoglycemia in Humans
NCT03241706 ACTIVE_NOT_RECRUITING PHASE1